Advanced cervical cancer responds poorly to current treatment modalities. The response rates are low and brief duration. Cisplatin was an active drugs in cervical cancer, 5-fluorouracil was also an interesting drug that showed promising activity on cervical cancer.We conducted trial to determine the efficacy and safety of 5-fluorouracil and cisplatin combination in cervical carcinoma. From July 2002 to July 2003, twenty one patients with recurrent, persistent or metastatic cervical cancer were treated with a combination of cisplatin 75 mg/m 2 and 5-fluoruracil 600 mg/m 2 , day 1, every 21 days. Eligibility criteria included: age >18 yrs, PS <2, <2 prior chemotherapy regimens, adequate bone marrow, kidney and liver function, measurable or evaluable disease. Median age is 45,1 years (range 30–68). Histology were 19 squamous cell, 1 adenocarcinoma and one adenosquamous cell carcinoma. Two patients had received prior chemotherapy for recurrent disease, twelve had received prior radiochemotherapy. Seventeen patients are evaluable for response and all for toxicity.Median chemotherapy cycles was 4,5 (range 1–9). The overall response rate is 43%. Complete response was not observed. Stable disease was achieved in 24% of patients. 33% of patients progressed while on treatment. Median time to progression and overall survival had not been reached. Toxicity was manageable. In 28% of patients grade 3 anaemia was documented, in 7% grade 4 neutropenia and grade 2 trombocytopenia. Grade 3 vomiting/nausea was observed in 28% of patients. In one case grade 3 diarrhoea with mucositis was documented.5-fluorouracil with combination with cisplatin is an active regimen for recurrent, persistent or metastatic cervical cancer (ORR- 43%). This combination is well tolerated and less toxic. More data will be provided in future on the disease free survival and overall survival.